

length and complexity of the labeling procedure and the limited availability and expense of the radionuclide. However, because of its potential diagnostic use, it is anticipated that this test will be more widely available in the future.

MYRA V. DRICKMAN, MD  
JUDITH G. ROSE, MD

#### REFERENCES

- Thakur ML, Coleman RE, Mayhall CG, et al: Preparation and evaluation of  $^{111}\text{In}$ -labeled leukocytes as an abscess imaging agent in dogs. *Radiology* 119:731-732, Jun 1976
- Doherty PW, Bushberg JT, Lipton MJ, et al: The use of indium-111-labeled leukocytes for abscess detection. *Clin Nucl Med* 3:108-110, Mar 1978
- Knochel JQ, Koehler PR, Lee TG, et al: Diagnosis of abdominal abscesses with computed tomography, ultrasound, and  $^{111}\text{In}$  leukocyte scans. *Radiology* 137:425-432, Nov 1980

### Detection of Acute Myocardial Infarction by Pyrophosphate $^{99\text{m}}\text{Tc}$ Scintigraphy

SIX YEARS AGO the use of scintigraphy with pyrophosphate labeled with technetium 99m was introduced as a method to detect acute myocardial infarction (AMI). Subsequent experience has substantiated the initial reports of Bonte and Parkey, and a sensitivity in the range of 90 percent for detecting acute infarction has been observed. Ideally the study is done 36 to 48 hours after infarction has occurred, but positive studies have been reported during the first 24 hours. An early negative study should be followed up with a repeat test two to three days later.

Like most sensitive tests, this method is relatively nonspecific. For example, ventricular aneurysms, unstable angina, calcified valves and pericarditis have produced positive test results. Varying degrees of specificity can be attained, however, by grading the studies according to the

pattern as well as the intensity of the activity in the myocardium. The measurement of 90 percent sensitivity for diagnosing AMI is based on a grading by intensity level as the only criterion for determining positive findings. If the pattern of cardiac activity is also graded as either diffuse throughout the myocardium or localized to a specific wall of the myocardium, then the sensitivity decreases but the specificity increases considerably. In a coronary care unit two thirds of the patients with AMI will have a localized pattern of activity on the scintigrams. The specificity of this finding is 95 percent. Over a fourth of the patients will have the highest intensity grade in addition to the localized pattern, and in these patients specificity will be 99 percent.

Myocardial scintigraphy using pyrophosphate  $^{99\text{m}}\text{Tc}$  does not replace electrocardiography and should not be the first test ordered in evaluating a patient with chest pain. However, in those patients for whom a diagnosis remains uncertain, pyrophosphate scintigraphy can be extremely useful. In attempting to rule out AMI, a negative study offers a 90 percent probability that this diagnosis can be excluded. However, a localized pattern of the highest intensity grade is virtually diagnostic of AMI, and a localized pattern alone is very strong but not absolute evidence for AMI.

KENNETH P. LYONS, MD  
HAL OLSON, MD

#### REFERENCES

- Poliner LR, Buja LM, Parkey RW, et al: Clinicopathologic findings in 52 patients studied by technetium-99m stannous pyrophosphate myocardial scintigraphy. *Circulation* 59:257-267, Feb 1979
- Lyons KP, Olson H, Aronow W, et al: Sensitivity and improved specificity of a localized pattern of  $^{99\text{m}}\text{Tc}$  pyrophosphate myocardial scintigraphy for the diagnosis of acute myocardial infarction. *J Nucl Med* 20:660, Jun 1979
- Bonte FJ, Parkey RW, Graham KD, et al: A new method for radionuclide imaging of myocardial infarcts. *Radiology* 110:473-474, Feb 1974

### ADVISORY PANEL TO THE SECTION ON NUCLEAR MEDICINE

WILLIAM H. BLAHD, MD  
*Advisory Panel Chairman*  
*Section Editor*

*CMA Scientific Board Representative*  
*Los Angeles*

GILBERT GREENSPAN, MD  
*CMA Section Chairman*  
*San Diego*

LEONARD SWANSON, MD  
*CMA Section Secretary*  
*Los Angeles*

RICHARD MYERS, MD  
*CMA Section Assistant Secretary*  
*Berkeley*

NORMAN E. POE, MD  
*Loma Linda University*

JOSEPH KRISS, MD  
*Stanford University*

GERALD DENARDO, MD  
*University of California, Davis*

KENNETH LYONS, MD  
*University of California, Irvine*

DAVID KUHL, MD  
*University of California, Los Angeles*

WILLIAM L. ASHBURN, MD  
*University of California, San Diego*

ROBERT HATTNER, MD  
*University of California, San Francisco*

JAN SIEMSEN, MD  
*University of Southern California*  
*Los Angeles*

WILLIAM T. McLAUGHLIN, MD  
*Saratoga*

NAOMI ALAZRAKI TAYLOR, MD  
*San Diego*